Treating Metastatic Renal Cell Carcinoma:
A Workshop for Oncology Nurses

This program was presented as a continuing education symposium for oncology nurses during the ONS APN Conference and ONS 9th Annual IOL.

Thursday, November 13, 2008
7:30 – 9:30 pm (Pacific Time Zone)
Grand Ballroom A
Sheraton Seattle Hotel
Seattle, Washington

Release Date: November 2008
Expiration Date: October 2009
Estimated Time to Complete Activity: 1 hour 54 minutes (Adobe Flash Player and Adobe Acrobat Reader required)

Target Audience

Oncology nurses and nurse practitioners who care for patients with renal cell carcinoma (RCC).

Purpose

To educate nurses on the latest treatment and nursing management strategies for patients with metastatic RCC.

Program Overview

Led by RCC physician and nurse thought leaders, this symposium will highlight the latest clinical trial data likely to affect nursing practice in 2009 and describe best practices for managing treatment-related side effects. The program will begin with an overview of treatment options for patients with metastatic disease and review new clinical research. This will be followed by workshops on specific nursing management strategies for new classes of agents used for metastatic RCC, including mTOR, vascular endothelial growth factor, and multikinase inhibitors. An interactive question-and-answer activity will provide attendees with a working model for incorporating up-to-date standards and assessment tools into their routine nursing practices. The program will begin and end with knowledge-based questions to gauge participants’ understanding of learning objectives.

Learning Objectives

Upon completion of this program, participants should be better able to:

Identify current RCC treatment standards of care based on disease stage, patient performance status, and previous treatment exposure
Evaluate outstanding RCC research questions that will likely affect future treatment options, including the roles of mTOR, vascular endothelial growth factor, and multikinase inhibitors
Identify nursing management strategies to ensure safe drug administration of agents used to treat RCC
Identify nursing management strategies to minimize or alleviate symptoms associated with RCC treatments
Describe the critical importance of clinical trial participation and the nursing role in facilitating such discussions with patients and their families

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. IMER, Genentech BioOncology and Wyeth Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of IMER, Genentech BioOncology and Wyeth Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Conflicts of Interest

IMER requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by IMER for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Faculty

Laura S. Wood, MSN, RN, OCN^® (Chairperson)
Cleveland Clinic Taussig Cancer Center

Ms. Wood is coordinator of renal cancer clinical research in the Experimental Therapeutics Program at the Taussig Cancer Center of the Cleveland Clinic Foundation in Cleveland, Ohio. She received her master’s degree in nursing from Kent State University in Kent, Ohio. A national and international lecturer on topics related to oncology nursing, she has written journal articles on therapeutic approaches and nursing management strategies for the care of patients with cancer. Ms. Wood was the recipient of the 2004 Oncology Nursing Society Excellence in Biotherapy Nursing Award and the 2005 Emma Barr Award for Clinical Excellence from the Cleveland Clinic Foundation.

Laura S. Wood, RN, MSN, OCN®, reported a financial interest/relationship or affiliation in the form of: Speakers’ Bureau, Bayer Pharmaceuticals Corporation, Onyx Pharmaceuticals, Inc., Pfizer, Inc., and Wyeth Pharmaceuticals.

John A. Thompson, MD
University of Washington School of Medicine

Dr. Thompson is an oncology professor at the University of Washington School of Medicine in
Seattle. He obtained his medical degree at the University of Alabama. Dr. Thompson’s clinical research interests focus on the immunotherapy of cancer with cytokines and activated lymphocytes. He serves on the National Comprehensive Cancer Network Clinical Guidelines Committees for Melanoma and Occult Primary, the Southwest Oncology Group Melanoma and Lymphoma Committees, and the Cytokine Working Group. He has written numerous articles and abstracts on treatment of hematologic malignancies.

John Thompson, MD, reported a financial interest/relationship or affiliation in the form of: Speakers' Bureau, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Wyeth Pharmaceuticals, and ZymoGenetics.

Patricia A. Creel, BSN, RN, CCRP, OCN®
Duke University Medical Center

Ms. Creel is the senior lead clinical research associate in Genitourinary Medical Oncology at Duke University Medical Center, in Durham, North Carolina. She has more than 20 years of clinical, management, and oncology nursing experience. Ms. Creel is a national and international speaker on emerging therapies in kidney cancer and the nursing management of side effects from multitargeted therapies. She has written nursing educational publications in these areas.

Patricia A. Creel, BSN, RN, CCRP, OCN®, reported a financial interest/relationship or affiliation in the form of: Consultant, Pfizer, Inc., Wyeth Pharmaceuticals, and Novartis Pharmaceuticals Corporation; Speakers' Bureau, Wyeth Pharmaceuticals.

Accreditation Statements

This educational activity for 1.91 contact hours will be provided by IMER. IMER is an approved provider of continuing education by the Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

IMER is approved by the California Board of Registered Nursing, Provider Number 14763 for 2.29 contact hours.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Safeguards Against Commercial Bias

IMER affirms that the content and format of its CE activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, IMER employs several strategies to ensure the absence of commercial bias, including but not limited to review of all planned content for CE activities sponsored by IMER to ensure adherence to the American Nurses Credentialing Center’s criteria and operational requirements and the Accreditation Council for Continuing Medical Education’s content validation statements and resolution of any actual or perceived conflict of interest that exist. We employ three metrics as we review materials:

1. Fair balance

a.
Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter

b.
No single product or service is overrepresented when other equal competing products or services are available for inclusion

2.	Scientific objectivity of studies mentioned in the materials or used as the basis for content

3. Appropriateness of patient care recommendations made to learners

Privacy Policy

When you participate in an educational activity provided by IMER (“we”), we ask you for your name, degree, affiliation, street address, telephone number, fax number, and e-mail address (the “Information”). We use that Information in the following ways:

We use the Information to grade your posttest and to send you a certificate of completion of the educational activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give the Information to that company for that purpose only.

For each educational activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.

We may use the Information to invite you to participate in other educational activities that IMER or its affiliates may offer.

On occasion, the commercial supporter of a educational activity will ask us for a list of the people who participated in that activity, so that it may document the first level of outcomes-based evaluation in the educational activity (ie, who attended, which medical specialties/practices were represented, how this compares to the target audience, and whether the activity needs to be repeated because significant numbers of the target audience did not attend). In that event, we will provide the supporter with your name, title and affiliation, but we will request in writing that the supporter not contact you directly for any purpose.

If our company is acquired or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.

Any changes to our privacy policy will be posted here.

Method of Participation

There are no fees for participating and receiving nursing contact hours for this activity.

Participants must complete the posttest by recording the best answer to each question. Once you finished your test and completed the subsequent evaluation form, click submit test to send your responsed to us. Your test will be immediately reviewed and if you receive a passing grade of 70% or better, you will then be directed to print your certificate online.

Media

Web site

Treating Metastatic Renal Cell Carcinoma: A Workshop for Oncology Nurses